Northland Securities Estimates Brainsway Q1 Earnings

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) – Northland Securities issued their Q1 2026 earnings per share estimates for Brainsway in a research report issued on Thursday, January 22nd. Northland Securities analyst C. Byrnes forecasts that the company will post earnings per share of $0.08 for the quarter. The consensus estimate for Brainsway’s current full-year earnings is $0.08 per share. Northland Securities also issued estimates for Brainsway’s Q2 2026 earnings at $0.12 EPS, FY2026 earnings at $0.50 EPS and FY2027 earnings at $0.64 EPS.

A number of other equities research analysts have also weighed in on the stock. HC Wainwright upped their target price on shares of Brainsway from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Brainsway in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.00.

Brainsway Trading Up 4.4%

BWAY opened at $24.19 on Friday. The company has a market cap of $473.64 million, a price-to-earnings ratio of 80.63 and a beta of 1.19. The company’s fifty day moving average price is $18.73 and its two-hundred day moving average price is $16.02. Brainsway has a 1-year low of $7.84 and a 1-year high of $24.84.

Brainsway (NASDAQ:BWAY) last issued its earnings results on Tuesday, November 11th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.03). The firm had revenue of $13.51 million during the quarter, compared to the consensus estimate of $13.04 million. Brainsway had a return on equity of 9.46% and a net margin of 12.73%.

Institutional Investors Weigh In On Brainsway

A number of hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC grew its position in Brainsway by 61.5% during the first quarter. NewEdge Advisors LLC now owns 19,828 shares of the company’s stock valued at $188,000 after buying an additional 7,549 shares during the period. Huntleigh Advisors Inc. increased its stake in shares of Brainsway by 5.7% during the 2nd quarter. Huntleigh Advisors Inc. now owns 77,416 shares of the company’s stock worth $1,018,000 after purchasing an additional 4,143 shares during the last quarter. ARK Investment Management LLC increased its stake in shares of Brainsway by 6.1% during the 2nd quarter. ARK Investment Management LLC now owns 199,826 shares of the company’s stock worth $2,628,000 after purchasing an additional 11,498 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Brainsway in the 2nd quarter worth approximately $85,000. Finally, Eagle Global Advisors LLC lifted its stake in Brainsway by 19.3% in the third quarter. Eagle Global Advisors LLC now owns 74,326 shares of the company’s stock valued at $1,120,000 after purchasing an additional 12,000 shares during the last quarter. 30.11% of the stock is currently owned by institutional investors.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.